The Allergan Breast Implant Lymphoma Lawsuit is a massive federal litigation involving thousands of women who developed breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) after receiving Allergan’s BIOCELL textured breast implants. Consolidated as MDL No. 2921 in the U.S. District Court for the District of New Jersey, the case currently has 1,481 pending claims as of December 2025, with the first bellwether trial scheduled for June 15, 2026. No global settlement has been reached, and individual payout amounts remain unestablished — but that bellwether trial is expected to be the turning point that drives serious settlement negotiations between the parties.
The stakes are significant. According to FDA data, 1,380 Medical Device Reports of BIA-ALCL have been filed since 2011, with 64 reported deaths worldwide. When a manufacturer was identified in those reports, approximately 90.4% of cases worldwide involved an Allergan implant, and 84% — or 481 cases — were specifically tied to Allergan’s textured products. Allergan issued a worldwide voluntary recall of all BIOCELL textured breast implants and tissue expanders on July 24, 2019, at the FDA’s request. This article covers the science behind BIA-ALCL, the current state of the litigation, what the bellwether trial could mean for plaintiffs, and what affected individuals should know about filing a claim.
Table of Contents
- What Is the Allergan Breast Implant Lymphoma Lawsuit and Who Does It Affect?
- Understanding BIA-ALCL — The Cancer Linked to Textured Breast Implants
- The MDL Timeline — From Recall to Bellwether Trial
- What Compensation Could Allergan Breast Implant Plaintiffs Receive?
- Filing a Claim — Deadlines, Eligibility, and Common Pitfalls
- Allergan’s Recall and the FDA’s Role in the Litigation
- What Happens After the Bellwether Trial — Outlook for 2026 and Beyond
- Conclusion
- Frequently Asked Questions
What Is the Allergan Breast Implant Lymphoma Lawsuit and Who Does It Affect?
The Allergan Breast Implant Lymphoma lawsuit targets Allergan, now a subsidiary of AbbVie, for allegedly manufacturing and selling textured breast implants that caused BIA-ALCL in patients. BIA-ALCL is a rare type of non-Hodgkin’s lymphoma that develops not in the breast tissue itself but in the scar tissue and fluid surrounding the implant. The disease is primarily associated with textured implants — not smooth ones — which is a critical distinction for anyone trying to determine whether they may be affected. Plaintiffs in the MDL allege that Allergan knew or should have known about the elevated cancer risk linked to its textured products and failed to adequately warn patients and surgeons. The litigation affects a broad population. Many of the women who received BIOCELL textured implants did so for reconstructive purposes after mastectomy, while others had cosmetic augmentation. In both cases, these were individuals who trusted that a FDA-cleared medical device was safe.
Consider a breast cancer survivor who, after completing treatment, chose reconstruction with Allergan’s textured implants only to face a second cancer diagnosis years later. That is the reality for hundreds of plaintiffs in this MDL. The lawsuit is not limited to those already diagnosed with BIA-ALCL — some claims involve women who underwent surgical explantation (implant removal) as a preventive measure after the recall, incurring significant medical costs and physical trauma. The FDA first identified a possible link between breast implants and ALCL back in 2011, but it took eight more years before the recall happened. That gap is central to the plaintiffs’ case. During those years, Allergan continued selling BIOCELL products while reports of BIA-ALCL accumulated. Plaintiffs argue this delay caused preventable harm.
Understanding BIA-ALCL — The Cancer Linked to Textured Breast Implants
Breast implant-associated anaplastic large cell lymphoma is not breast cancer. That distinction matters both medically and legally. BIA-ALCL is a cancer of the immune system — specifically a type of T-cell lymphoma — that grows in the capsule of scar tissue the body forms around a breast implant. Symptoms often include persistent swelling, pain, lumps near the implant, or fluid collection (called a seroma) that develops long after the surgical site should have healed. Some patients are diagnosed years or even a decade after implantation. When caught early and treated with complete surgical removal of the implant and surrounding capsule, outcomes are generally favorable. However, if the disease progresses beyond the capsule, treatment may require chemotherapy, radiation, or both, and the prognosis worsens considerably. The textured surface of certain implants appears to be the key risk factor.
Textured implants were designed to reduce the risk of capsular contracture — a painful hardening of scar tissue — by encouraging tissue to adhere to the implant surface. Ironically, that same texturing process may create the conditions for chronic inflammation that triggers BIA-ALCL in susceptible individuals. Smooth implants have a dramatically lower association with the disease. This is why the 2019 recall targeted Allergan’s BIOCELL textured line specifically, not all Allergan breast implants. However, if you have smooth implants, that does not mean your risk is zero — the FDA has noted rare cases associated with smooth-surface devices. It simply means the overwhelming statistical association points to textured products. Anyone experiencing unusual symptoms around a breast implant, regardless of type, should consult their physician. The FDA has been clear that it does not recommend prophylactic removal for patients who are asymptomatic, but monitoring and awareness are essential.
The MDL Timeline — From Recall to Bellwether Trial
The litigation’s timeline tells a story of slow-building scientific evidence followed by rapid legal action. The FDA flagged a possible implant-ALCL connection in 2011, and over the next several years, case reports accumulated in the medical literature and through the agency’s adverse event reporting system. By 2019, the evidence was strong enough for the FDA to request — and Allergan to agree to — a worldwide recall of BIOCELL textured products. Lawsuits had already been filed, and in 2019 the Judicial Panel on Multidistrict Litigation consolidated them into MDL No. 2921 in the District of New Jersey. Since consolidation, the case has moved through years of discovery, expert development, and procedural battles. In October 2025, in-person mediation sessions were held before Judge Welsh on October 7 and 10, with the court directing parties to continue good-faith negotiations.
Those sessions did not produce a global settlement, which is not unusual for complex product liability MDLs — it often takes a trial verdict or imminent trial date to create the pressure needed for meaningful settlement offers. The first bellwether trial is now set for June 15, 2026, focused on a surgical explant case. The court has not yet determined whether this will be a single-plaintiff or multi-plaintiff trial, and pretrial disclosures, deposition designations, and trial exhibit lists are due by April 22, 2026. Bellwether trials serve a specific purpose in MDL litigation. They are test cases designed to give both sides — and the court — a sense of how juries respond to the evidence. The outcomes of bellwether trials frequently shape the terms of any eventual global settlement. A large plaintiff verdict could push Allergan toward a more generous settlement; a defense verdict could have the opposite effect. For the 1,481 plaintiffs currently waiting, the June 2026 trial date is the most important milestone on the calendar.
What Compensation Could Allergan Breast Implant Plaintiffs Receive?
The honest answer is that no one knows yet. No global settlement has been reached, and individual estimated payout amounts have not been established. The June 2026 bellwether trial is widely expected to be the catalyst for serious settlement discussions. Until a jury puts a number on a specific plaintiff’s injuries, both sides are negotiating in the abstract to some degree. What we do know is that Allergan has previously paid $2.75 million to resolve a related lawsuit filed by three health benefit plans — entities that sought reimbursement for medical costs they covered for BIA-ALCL patients.
That figure, while notable, is not directly comparable to what individual plaintiffs with cancer diagnoses might receive. In other medical device MDLs, individual settlements have ranged from tens of thousands to millions of dollars depending on the severity of injury, the strength of causation evidence, and the plaintiff’s specific circumstances. A plaintiff who was diagnosed with BIA-ALCL, underwent explantation surgery, and required chemotherapy would likely be in a different compensation tier than someone who had a preventive explant without a cancer diagnosis. The tradeoff plaintiffs face is a familiar one in mass tort litigation: settle for a known amount or hold out for potentially more at trial while accepting the risk of getting less — or nothing. Plaintiffs who join a global settlement, if one is eventually offered, typically receive guaranteed compensation but must accept the terms set by the settlement grid. Those who opt out and pursue individual trials retain the possibility of larger verdicts but face years of additional litigation and the uncertainty of a jury outcome.
Filing a Claim — Deadlines, Eligibility, and Common Pitfalls
Eligibility for the Allergan Breast Implant Lymphoma Lawsuit generally requires that the plaintiff received an Allergan BIOCELL textured breast implant or tissue expander and either developed BIA-ALCL or underwent explantation surgery due to the recall and associated cancer risk. Medical records documenting the type of implant, the diagnosis, and the treatment are essential to building a viable claim. One common pitfall is that some patients do not know the exact manufacturer or model of their implants — surgical records, implant registration cards, or records from the surgeon’s office are the best sources for this information. Statutes of limitations vary by state, and this is where timing becomes critical. In many states, the clock starts when the plaintiff knew or should have known about the connection between their implant and their injury — which could be the date of diagnosis, the date of the recall announcement, or some other trigger.
However, if you have been sitting on a potential claim for years without taking action, you risk being time-barred regardless of the merits of your case. The MDL consolidation does not pause individual state statutes of limitations. A warning worth emphasizing: not every law firm advertising Allergan breast implant cases has the resources or experience to handle complex product liability litigation effectively. Mass tort advertising has exploded in recent years, and some firms function primarily as case aggregators that sign clients and then refer them to other attorneys. Plaintiffs should ask prospective counsel directly whether the firm will be handling their case through trial or referring it, what their experience with medical device litigation looks like, and how communication will work throughout what could be a multi-year process.
Allergan’s Recall and the FDA’s Role in the Litigation
The July 2019 recall was a pivotal moment. Allergan’s voluntary recall of all BIOCELL textured breast implants and tissue expanders came at the FDA’s request, following years of mounting evidence. By that point, the FDA had been tracking BIA-ALCL reports through its Medical Device Report system and identified that Allergan’s textured products were disproportionately represented. The agency’s data showed that 84% of cases where the manufacturer was identified — 481 of them — involved Allergan textured implants.
That statistic has become one of the most cited pieces of evidence in the litigation. The FDA’s role, however, has also drawn criticism from plaintiffs who argue the agency should have acted sooner. The 2011 identification of a possible link was followed by years of safety communications, advisory committee meetings, and data collection — but no recall until 2019. France and other countries pulled Allergan textured implants from the market before the United States did. For plaintiffs, this delay is part of the broader narrative of institutional failure that allowed preventable injuries to occur.
What Happens After the Bellwether Trial — Outlook for 2026 and Beyond
The June 15, 2026 bellwether trial will likely define the trajectory of this litigation for years to come. If the jury returns a substantial verdict for the plaintiff, expect Allergan and its parent company AbbVie to face intensified pressure to negotiate a global settlement. If the defense prevails, the path forward becomes murkier — though it would not necessarily end the litigation, since additional bellwether cases with different fact patterns could still proceed. Beyond the courtroom, the Allergan litigation has already changed the landscape of breast implant safety.
The FDA has strengthened its post-market surveillance of breast implants, implemented new labeling requirements, and created a patient decision checklist that surgeons must review with patients before implantation. For the 1,481 plaintiffs currently in MDL No. 2921, the fight is far from over. But the approaching trial date is the most concrete sign yet that resolution — whether through verdict or settlement — is on the horizon.
Conclusion
The Allergan Breast Implant Lymphoma Lawsuit represents one of the most significant medical device litigations of the past decade. With 1,481 cases consolidated in MDL No. 2921, FDA data linking approximately 90% of identified BIA-ALCL cases to Allergan products, and 64 reported deaths worldwide, the stakes for both plaintiffs and the defendant are enormous.
The first bellwether trial, scheduled for June 15, 2026, will be a defining moment — setting the stage for potential global settlement discussions or further trials. For anyone who received Allergan BIOCELL textured breast implants and has been diagnosed with BIA-ALCL or undergone explantation surgery, the time to evaluate your legal options is now. Statutes of limitations continue to run, evidence becomes harder to obtain over time, and the litigation is approaching its most critical phase. Consult with an experienced product liability attorney who can assess your specific situation, help you gather the necessary medical documentation, and advise you on whether joining the MDL or pursuing an individual claim makes the most strategic sense for your case.
Frequently Asked Questions
What is BIA-ALCL and how is it different from breast cancer?
BIA-ALCL is breast implant-associated anaplastic large cell lymphoma, a rare type of non-Hodgkin’s lymphoma. Unlike breast cancer, it develops in the scar tissue and fluid surrounding the implant, not in the breast tissue itself. It is a cancer of the immune system, not a solid tumor of the breast.
Which Allergan implants were recalled?
Allergan issued a worldwide voluntary recall on July 24, 2019 of all BIOCELL textured breast implants and tissue expanders. Smooth-surface Allergan implants were not included in the recall.
Has a settlement been reached in the Allergan breast implant lawsuit?
No. As of early 2026, no global settlement has been finalized. Mediation sessions occurred in October 2025, and the court has directed parties to continue good-faith negotiations. The first bellwether trial, scheduled for June 15, 2026, is expected to be a major driver of settlement discussions.
How much compensation could plaintiffs receive?
Individual payout amounts have not been established. Allergan previously paid $2.75 million to resolve a related lawsuit filed by health benefit plans, but individual plaintiff compensation will depend on factors like diagnosis severity, treatment required, and the outcome of bellwether trials.
Should I have my Allergan textured implants removed if I have no symptoms?
The FDA does not recommend prophylactic removal for asymptomatic patients. However, you should discuss your individual risk factors and monitoring plan with your physician. If you experience swelling, pain, lumps, or fluid collection around an implant, seek medical evaluation promptly.
Is it too late to file a lawsuit?
It depends on your state’s statute of limitations and when you became aware of the connection between your implant and BIA-ALCL. Deadlines vary significantly by state. Consulting with a product liability attorney as soon as possible is critical to preserving your legal rights.